Marksans Pharma Limited
Stock Forecast, Prediction & Price Target
Marksans Pharma Limited Financial Estimates
Marksans Pharma Limited Revenue Estimates
Marksans Pharma Limited EBITDA Estimates
Marksans Pharma Limited Earnings per Share Estimates
| Passed | Analyst forecast | ||||||
|---|---|---|---|---|---|---|---|
| Metric | 3/31/2021 | 3/31/2022 | 3/31/2024 | 3/31/2026 | |||
Revenue
% change YoY
| ₹13.68B N/A | ₹14.80B 8.16% | ₹21.77B 47.10% | Avg: ₹31.79B Low: ₹31.79B High: ₹31.79B avg. 45.99% | |||
Net Income
% change YoY
| ₹2.38B N/A | ₹1.84B -22.62% | ₹3.13B 69.96% | Avg: ₹4.85B Low: ₹4.85B High: ₹4.85B avg. 54.62% | |||
EBITDA
% change YoY
| ₹3.46B N/A | ₹2.94B -14.93% | ₹5.08B 72.79% | Avg: ₹6.68B Low: ₹6.68B High: ₹6.68B avg. 31.28% | |||
EPS
% change YoY
| $5.76 N/A | $4.51 -21.70% | $6.92 53.43% | Avg: $10.7 Low: $10.7 High: $10.7 avg. 54.62% | |||
Operating Expenses
% change YoY
| ₹4.31B N/A | ₹5.15B 19.55% | ₹3.28B -36.17% | Avg: ₹3.91B Low: ₹3.91B High: ₹3.91B avg. 18.91% | |||
FAQ
What is Marksans Pharma Limited stock earnings growth forecast?
Wall Street analysts estimate the annual average earnings growth rate of 54.62% in 2026-2026.
We have gathered data from N/A analysts. Their low estimate is 4.85B, average is 4.85B and high is 4.85B.
What is Marksans Pharma Limited stock revenue growth forecast?
Wall Street analysts forecast annual average revenue growth of 45.99% in 2026-2026.
We have gathered data from N/A analysts. Their low revenue estimate is ₹31.79B, average is ₹31.79B and high is ₹31.79B.
What is Marksans Pharma Limited stock earnings per share growth forecast?
Wall Street analysts forecast annual average earnings growth of 54.62% in 2026-2026.
We have gathered data from N/A analysts. Their low earnings per share estimate is $10.7, average is $10.7 and high is ₹10.7.